News
Phase III CheckMate -743 trial of Opdivo + Yervoy shows efficacy in malignant pleural mesothelioma.- BMS
Bristol Myers Squibb announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a significant improvement in overall survival (OS) in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM) in the Phase III CheckMate -743 clinical trial. With a minimum follow-up of 22 months, treatment with Opdivo plus Yervoy reduced the risk of death by 26%, demonstrating a median OS of 18.1 months vs. 14.1 months for platinum-based standard of care chemotherapy (Hazard Ratio [HR]: 0.74 [96.6% Confidence Interval [CI]: 0.60, 0.91]; p=0.002). At two years, 41% of patients treated with the Opdivo plus Yervoy combination were alive, compared to 27% of patients treated with chemotherapy. The primary endpoint of the trial was OS in all randomized patients. Key secondary endpoints included objective response rate (ORR), disease control rate (DCR) and progression-free survival (PFS). Exploratory endpoints included safety, pharmacokinetics, immunogenicity and patient reported outcomes. The safety profile of Opdivo plus Yervoy was consistent with previously reported studies, and no new safety signals were observed. These data will be presented at the 2020 World Conference on Lung Cancer Virtual Presidential Symposium.
Condition: Malignant Mesothelioma
Type: drug